Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indoximod + Tergenpumatucel-L + Docetaxel in Advanced NSCLC
NCT02460367Phase 1Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indoximod and tergenpumatucel-l in non-small cell lung cancer (NSCLC), sponsored by Lumos Pharma, Inc. Primary endpoints: Regimen Limiting Toxicity at 6 weeks and Progression Free Survival at 18 months. Started Jan 2016; status: terminated.
02
Drugs
indoximodtergenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02460367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460367.